What has the Gene and Related Therapies Research Advisory Panel (GTRAP) done in relation to proposed trials of xenotransplantation?
Overall, GTRAP has had seven years of experience in advising on human clinical trials involving the use of gene therapy. This experience is directly relevant for the assessment of xenotransplantation research because gene therapy involves the use of similar genetic technology to xenotransplantation. When the role of GTRAP was expanded in 1999 to include xenotransplantation, two experts in xenotransplantation and one expert in the infectious diseases of most relevance for xenotransplantation joined the panel. Since then, GTRAP has reviewed one xenotransplantation research proposal, and recommended it did not proceed because of lack of evidence of benefit to the patient, unquantifiable potential community risk and concerns about the biological safety of the source material.
Related Questions
- What type of research needs authorization from the Research Advisory Panel of California (RAPC)? How do I get authorization from RAPC?
- What has the Gene and Related Therapies Research Advisory Panel (GTRAP) done in relation to proposed trials of xenotransplantation?
- When will therapies from human gene transfer research be available?
